Navigation Links
CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS

LOS ANGELES--(BUSINESS WIRE)--Jun 25, 2007 - CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today reported safety and tolerability results from its previously announced double-blind, placebo-controlled, rising multiple dose clinical trial in healthy volunteers with its drug candidate arimoclomol. CytRx believes that the results of this trial support the use of arimoclomol in future clinical trials, including its ALS Phase IIb clinical trial, at doses up to six-fold higher than that used in its previous Phase IIa clinical trials for ALS.

CytRx plans to begin its Phase IIb clinical trial in the second half of this year, subject to U.S. Food and Drug Administration (FDA) clearance. As previously announced, this trial, planned to include approximately 390 ALS patients enrolled at 30 to 35 U.S. and Canadian clinical sites, was designed to monitor changes in the progression of disease symptoms and would be completed about 18 months after the beginning of patient enrollment. Following consultation with the FDA, CytRx is now considering various options, including increasing the size and duration of the planned trial and/or conducting a second efficacy clinical trial for ALS, possibly in parallel with the Phase IIb trial, to provide additional data to support a possible approval decision by the FDA.

CytRx expects to announce results of its recently-completed six-month open-label extension trial with arimoclomol for ALS later this week.

"It is rewarding to see significant progress toward our goal of initiating the Phase IIb clinical trial for arimoclomol this year," stated CytRx's President and CEO Steven A. Kriegsman. "Based on the results of this clinical trial we plan to proceed with a dose that is four times greater than that used in our previous Phase IIa ALS clinical trials. These study results will help us optimize
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:7/27/2015)... 2015 Research and Markets ( ... the "Wound Care -Traditonal, Advanced And ... And Forecasts" report to their offering. ... of the global Wound Care products market, ... offerings, competitive shares, financial performance, technology developments ...
(Date:7/27/2015)... 2015 According to the new ... (2014-2019) by Type (DNA ISH, RNA ISH), By Application ... (Hospitals, Pharma & Biotech Companies, Research Labs, CROs)", The ... 2014 and is estimated to reach $681.0 million by ... period, 2014 to 2019. Browse through the ...
(Date:7/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/v4wlnk/key_pharma_news ) has ... News Issue" newsletter to their offering. ... oncology pipeline and serves as a statement of ... 2015, with a large-scale potentially transformative acquisition by ... Pharma News covers all major developments in the ...
Breaking Medicine Technology:Global Wound Care Markets 2015-2020 - Traditonal, Advanced And Regenerative: Competitors And Opportunities 2Global In-Situ Hybridization Market to be Worth $681.0 Million by 2019 2Global In-Situ Hybridization Market to be Worth $681.0 Million by 2019 3Key Pharma News Issue - Gilead will make further oncology deals in 2015 2Key Pharma News Issue - Gilead will make further oncology deals in 2015 3
... Colo., Oct. 14, 2011 Data presented at ... in Chicago, IL show that the pretreatment blood-based ... carcinoma (RCC) patients treated with a combination of ... by survival outcomes.   Patients who tested VeriStrat ...
... Pharmaceuticals, Inc. announced Friday a significant expansion of its ... methyl, and to continue advancing its earlier-stage pipeline. ... Paul Audhya, MD, as Vice President of ... Ph.D., as Vice President and Chief Regulatory and Compliance ...
Cached Medicine Technology:VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients 2VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients 3Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors 2Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors 3
(Date:7/28/2015)... ... July 28, 2015 , ... North American Seminars will ... fall of 2015 . These seventeen courses are pre-approved for CME credit ... Functional Mobility in the Older Adult , August 22, 2015 - August ...
(Date:7/28/2015)... ... ... the Veterans Fund of the United States, managing the United Veteran Beacon House (UVBH) for ... to help homeless Veterans by giving them “A hand up – not a hand out.” ... assists and supports Vets through the Veterans Fund of the United States (VFUS), ...
(Date:7/27/2015)... ... July 28, 2015 , ... Combination Product GMP Compliance:, Understanding FDA’s New ... http:// http://www.fdanews.com/comboproductgmpcompliance , Manufacturing a drug or device is hard ... can get messy in a hurry. In a 46-page draft guidance released in January, ...
(Date:7/27/2015)... , ... July 28, 2015 , ... The National ... inductee into the NAPW VIP Woman of the Year Circle. She is recognized with ... 200 operating Local Chapters, NAPW is the nation’s leading networking organization exclusively for professional ...
(Date:7/27/2015)... ... July 27, 2015 , ... ... wound center management. Earlier this year Wound Care Advantage beta launched ... for WCA wound centers. Customized learning paths allow for clinicians, physicians, hyperbaric ...
Breaking Medicine News(10 mins):Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 2Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 3Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 4Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 5Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 6Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 7Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 8Health News:Veterans Fund of the United States Launches “Adopt A Homeless Veteran” Campaign 2Health News:Veterans Fund of the United States Launches “Adopt A Homeless Veteran” Campaign 3Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 2Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 3Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 4Health News:NAPW Inducts Deana Skidmore, Assistant Director of Nursing at Wilton Meadows Rehablilitation and Health Care Center, Into its VIP Woman of the Year Circle 2Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 2Health News:Wound Care Advantage Launches Luvo University An Online Hub For Wound Care Education and Training 3
... distributed to Kids attending the event with their parents. Food, Entertainment ... ,Florida KidCare - Back to School - Enrollment Fair Sunday, August 3, ... - Shoppes of Cresthaven - (Military Trail & Cresthaven Blvd) West Palm ... ...
... 1 Mark Merritt, President,of the Pharmaceutical ... response to new comparative effectiveness legislation,introduced late ... Max Baucus,(D-Mont.) and Senate Budget Committee Chair ... Baucus and Conrad for helping advance the,discussion ...
... 1 Community-based oral health,programs in Michigan, Ohio, ... to $5,000 from the Delta Dental Foundation,s third ... by Nancy E. Hostetler,senior vice president of the ... of $70,000 will be awarded in competitive grants,this ...
... it,s unclear whether treating the breathing disorder cuts the ... News) -- The interrupted nighttime breathing of sleep apnea ... report. , Earlier studies have linked sleep apnea to ... in sleep centers rather than in the general community. ...
... 2008) -- Quality of care varies greatly for the treatment ... country and category of health care facility, suggesting the potential ... to a new study that was published in the Aug. ... (2008: Vol. 26, Issue 22). , The inconsistencies in care ...
... of Medicine have discovered that a protein called FOXA2 controls ... liver. FOXA2 may become the focus for new therapies to ... study was published online this week in Nature Medicine ... in the gall bladder and transported through ducts to the ...
Cached Medicine News:Health News:Florida KidCare News Conference and Back to School Enrollment Fair 2Health News:Delta Dental Foundation Calls for Applicants for Annual Community Mini-Grant Program 2Health News:Sleep Apnea Boosts Death Risk 2Health News:Sleep Apnea Boosts Death Risk 3Health News:Disparities in prostate cancer treatment suggest ways to improve care 2Health News:Penn researchers find a new role for a 'Foxy Old Gene' 2
... provide you with everything you need ... evoked potential, or electro-oculogram. The ultra-bright ... to perform ERGs you never imagined ... negative response, and s-cone ERGs. Wireless ...
The PersonalLAB junior is an automated microplate analyzer capable of fully automating immunoenzymatic techniques using a microplate format, per the reagent manufacturer's instruction for use and spe...
... designed for high throughput microplate processing. The ... Stacker that handles up to 60 microplates ... model is equipped with a dual direct ... may be interfaced to increase flexibility as ...
... Processor is a precise, reliable and ... has been designed for OEM production. ... customised according to the method bottles ... able to process automatically the whole ...
Medicine Products: